Bicycle Therapeutics plc
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Corbus Pharmaceuticals Holdings, Inc. stock sank after CRB-701 Phase 1/2b OPSCC/cervical data; see ORR, competition and outlook. Click for more pm CRBP stock.
European equities traded in the US as American depositary receipts were trending slightly higher lat
In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for
European equities traded in the US as American depositary receipts were tracking lower late Thursday
European equities traded in the US as American depositary receipts were trending marginally higher l
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 1.14 percent increase over losses of $(0.88) per share
Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancerHuman imaging data provides further...
CAMBRIDGE, England & BOSTON, April 21, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago.
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral
Bicycle Therapeutics plc announced updates from its EphA2 pipeline at the American Association for Cancer Research Annual Meeting 2026. Phase 1 combination data of 6.5mg/m2 Second Quarter nuzefatide...
CAMBRIDGE, England & BOSTON, April 20, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Bicycle Therapeutics Investor Presentation April 2026 Bicycle Therapeutics: Pioneering a new, differentiated class of...
AACR Annual Meeting 2026 Data HighlightsNuzefatide pevedotin (nuzefatide), formerly BT5528, a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), Phase 1/2 data in combination with
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Bicycle Therapeutics plc is one of the best biotech stocks on this list. TheFly reported on April 8 that Morgan Stanley reduced its price target on BCYC to $12 from $13 while maintaining an Equal Weight rating. The firm updated […]
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Bicycle Therapeutics plc is one of the best biotech stocks on this list. TheFly reported on April 8 that Morgan Stanley reduced its price target on BCYC to $12 from $13 while maintaining an Equal Weight rating. The firm updated […]
European equities traded in the US as American depositary receipts were trending lower late Thursday
European equities traded in the US as American depositary receipts were trending lower late Thursday
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 979.3K | $4.54M | 0.01% | Added+72.8% | 2026-03-31 |
| TwoSigma | quant | 164.8K | $764.67K | 0.00% | Added+24.8% | 2026-03-31 |
| Citadel | multi-strat | 130.4K | $605.16K | 0.00% | Added+69.9% | 2026-03-31 |
| StateStreet | passive | 30.5K | $141.58K | 0.00% | Trimmed-56.5% | 2026-03-31 |
| TRowePrice | fundamental | 1.03M | $4.77K | 0.00% | Trimmed-12.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-07upcoming | -0.58 | — | — |
| 2026-04-30 | -0.67 | -0.87 | -29.37% |
| 2026-03-17 | -0.95 | -0.29 | +69.62% |
| 2025-10-30 | -1.07 | -0.85 | +20.40% |
| 2025-08-08 | -0.93 | -1.14 | -22.04% |
| 2025-05-01 | -0.81 | -0.88 | -8.81% |
| 2025-02-25 | -0.85 | -0.81 | +4.59% |
| 2024-10-31 | -0.78 | -0.72 | +7.46% |
| 2024-08-06 | -1.11 | -0.77 | +30.44% |
| 2024-05-02 | -1.21 | -0.62 | +48.68% |
| 2024-02-20 | -1.19 | -1.16 | +2.40% |
| 2023-11-02 | -1.06 | -1.26 | -18.73% |
| 2023-08-03 | -1.07 | -1.41 | -32.19% |
| 2023-05-04 | -0.96 | -1.30 | -36.02% |
| 2023-02-28 | -1.04 | -1.01 | +2.81% |
| 2022-11-03 | -0.91 | -0.96 | -6.03% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCYC | -2.29% | -14.73% | -33.76% | -42.94% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.26% | -10.09% | -30.31% | -55.63% |